Unknown

Dataset Information

Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.


ABSTRACT:

Background

Current checkpoint immunotherapy has shown potential to control cancer by restoring or activating the immune system. Nevertheless, multiple mechanisms are involved in immunotherapy resistance which limits the clinical benefit of checkpoint inhibitors. An immunosuppressive microenvironment is an important factor mediating the original resistance of tumors to immunotherapy. A previous report by our group has demonstrated that local angiotensin II (AngII) predominantly exists in a tumor hypoxic microenvironment where hypoxic tumour cells produced AngII by a hypoxia-lactate-chymase-dependent mechanism.

Results

Here, using 4T1 and CT26 syngeneic mouse tumor models, we found that local AngII in the tumor microenvironment was involved in immune escape of tumour cells and

SUBMITTER: Xie G 

PROVIDER: S-EPMC6134794 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature